Institute of Molecular Virology (IMV), Centre for Molecular Biology of Inflammation (ZMBE), University of Münster, Von-Esmarch-Str. 56, D-48149 Münster, Germany.
Biol Chem. 2011 Oct;392(10):837-47. doi: 10.1515/BC.2011.121.
Influenza is still one of the major plagues worldwide with the threatening potential to cause pandemics. In recent years, increasing levels of resistance to the four FDA approved anti-influenza virus drugs have been described. This situation underlines the urgent need for novel anti-virals in preparation for future influenza epidemics or pandemics. Although the anti-virals currently in use target viral factors such as the neuraminidase or the M2 ion channel, there is an increase in pre-clinical approaches that focus on cellular factors or pathways that directly or indirectly interact with virus replication. This does not only include inhibitors of virus-supportive signaling cascades but also interaction blockers of viral proteins with host cell proteins. This review aims to highlight some of these novel approaches that represent a paradigm change in anti-viral strategies against the influenza virus. Although most of these approaches are still in an early phase of preclinical development they might be very promising particularly with respect to the prevention of viral resistance to potential drugs.
流感仍然是全球主要的瘟疫之一，具有引发大流行的潜在威胁。近年来，已描述了对四种 FDA 批准的抗流感病毒药物的耐药性水平不断增加的情况。这种情况突出表明，迫切需要新型抗病毒药物，以应对未来的流感疫情或大流行。尽管目前使用的抗病毒药物针对病毒因素，如神经氨酸酶或 M2 离子通道，但越来越多的临床前方法侧重于直接或间接与病毒复制相互作用的细胞因子或途径。这不仅包括病毒支持信号级联的抑制剂，还包括病毒蛋白与宿主细胞蛋白相互作用的阻断剂。这篇综述旨在强调其中一些新方法，这些方法代表了抗流感病毒策略中的范式转变。尽管这些方法中的大多数仍处于临床前开发的早期阶段，但它们具有很大的前景，特别是在预防病毒对潜在药物产生耐药性方面。
